Active Systemic Treatment of Pancreatic Cancer
نویسندگان
چکیده
منابع مشابه
Systemic treatment of advanced pancreatic cancer.
Pancreatic cancer belongs to the most malignant gastrointestinal cancers and, in its advanced stage, remains a deadly disease for nearly all affected patients. Treatment of metastatic adenocarcinoma of the pancreas not only involves chemotherapy and targeted therapy, but also requires attention to accompanying comorbidities as well as frequently intensive supportive treatment and psychosocial s...
متن کاملPancreatic Cancer: Progress in Systemic Therapy.
BACKGROUND Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer-related deaths in the Western world. Due to lack of specific symptoms and no accessible precursor lesions, primary diagnosis is commonly delayed, resulting in the identification of only 15-20% of patients with potentially curable disease. The major limiting factor is an already locally advanced or metastatic disease...
متن کاملSystemic Chemotherapy in Advanced Pancreatic Cancer
Pancreatic cancer remains one of the most lethal cancers. These patients often have multiple symptoms, and integrated supportive care is critical in helping them remain well for as long as possible. Fluorouracil-based chemotherapy is known to improve overall survival (OS) by approximately 3 months, compared to the best supportive care alone. A 1997 study comparing gemcitabine and fluorouracil t...
متن کاملPancreatic Cancer Treatment
Pancreatic cancer is one of the most aggressive and lethal human cancers, with more than 200, 000 deaths worldwide every year. Despite recent efforts, conventional treatment approaches, such as surgery, classic chemotherapy, radiotherapy, biologic therapy and palliative care have only slightly improved patient outcomes. Among the conventional chemotherapies the combination of abraxane (nab-pacl...
متن کامل[Surgical treatment of pancreatic cancer].
Surgery remains the only hope for cure in pancreatic cancer. The most common procedures are reviewed. Postoperative morbidity and mortality below 30% and 5%, respectively, are the standard. The benefit of extended lymph node dissection and portal-mesenteric vein resection is dubious. Selected patients with locally advanced cancer may be down-staged with chemo-radiotherapy and eventually resecte...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of the National Comprehensive Cancer Network
سال: 2017
ISSN: 1540-1405,1540-1413
DOI: 10.6004/jnccn.2017.0084